Women and Diabetes: Preventing Heart Disease in a New Era of Therapies

Despite major advances in cardiovascular research over the past decade, women with type 2 diabetes have a high risk of cardiovascular events. Several factors contribute to the poor prognosis for women, including higher levels of frailty and comorbidities, but their cardiovascular risk is underestima...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Giuseppe Galati, Pierre Sabouret, Olga Germanova, Deepak L Bhatt
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2021
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/ec4ff1ff8efb43c3b5eb45f3380f1784
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ec4ff1ff8efb43c3b5eb45f3380f1784
record_format	dspace
spelling	oai:doaj.org-article:ec4ff1ff8efb43c3b5eb45f3380f17842021-12-04T16:05:08ZWomen and Diabetes: Preventing Heart Disease in a New Era of Therapies10.15420/ecr.2021.221758-37641758-3756https://doaj.org/article/ec4ff1ff8efb43c3b5eb45f3380f17842021-10-01T00:00:00Zhttps://www.ecrjournal.com/articleindex/ecr.2021.22https://doaj.org/toc/1758-3756https://doaj.org/toc/1758-3764Despite major advances in cardiovascular research over the past decade, women with type 2 diabetes have a high risk of cardiovascular events. Several factors contribute to the poor prognosis for women, including higher levels of frailty and comorbidities, but their cardiovascular risk is underestimated and there is suboptimal implementation and uptitration of new evidence-based therapies, leading to high morbidity and mortality. Recent studies highlight the need for better management of diabetes in women that can be pursued and achieved in light of recent results from randomised controlled trials demonstrating evidence of the benefits of new therapeutic strategies in improving cardiovascular outcomes and quality of life of women covering the entire cardiovascular continuum. This review critically discusses the multiple benefits for women of new pharmacological treatments, such as glucagon-like peptide-1 receptor agonists, sodium–glucose cotransporter type 2 inhibitors (SGLT2i), proprotein convertase subtilisin/kexin type 9 inhibitors, inclisiran, icosapent ethyl and bempedoic acid in preventing cardiovascular events, and treatments, such as angiotensin receptor neprilysin inhibitors, SGLT2i, vericiguat and omecamtiv mecarbil, for preventing heart failure.Giuseppe GalatiPierre SabouretOlga GermanovaDeepak L BhattRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENEuropean Cardiology Review , Vol 16, Iss , Pp - (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Giuseppe Galati Pierre Sabouret Olga Germanova Deepak L Bhatt Women and Diabetes: Preventing Heart Disease in a New Era of Therapies
description	Despite major advances in cardiovascular research over the past decade, women with type 2 diabetes have a high risk of cardiovascular events. Several factors contribute to the poor prognosis for women, including higher levels of frailty and comorbidities, but their cardiovascular risk is underestimated and there is suboptimal implementation and uptitration of new evidence-based therapies, leading to high morbidity and mortality. Recent studies highlight the need for better management of diabetes in women that can be pursued and achieved in light of recent results from randomised controlled trials demonstrating evidence of the benefits of new therapeutic strategies in improving cardiovascular outcomes and quality of life of women covering the entire cardiovascular continuum. This review critically discusses the multiple benefits for women of new pharmacological treatments, such as glucagon-like peptide-1 receptor agonists, sodium–glucose cotransporter type 2 inhibitors (SGLT2i), proprotein convertase subtilisin/kexin type 9 inhibitors, inclisiran, icosapent ethyl and bempedoic acid in preventing cardiovascular events, and treatments, such as angiotensin receptor neprilysin inhibitors, SGLT2i, vericiguat and omecamtiv mecarbil, for preventing heart failure.
format	article
author	Giuseppe Galati Pierre Sabouret Olga Germanova Deepak L Bhatt
author_facet	Giuseppe Galati Pierre Sabouret Olga Germanova Deepak L Bhatt
author_sort	Giuseppe Galati
title	Women and Diabetes: Preventing Heart Disease in a New Era of Therapies
title_short	Women and Diabetes: Preventing Heart Disease in a New Era of Therapies
title_full	Women and Diabetes: Preventing Heart Disease in a New Era of Therapies
title_fullStr	Women and Diabetes: Preventing Heart Disease in a New Era of Therapies
title_full_unstemmed	Women and Diabetes: Preventing Heart Disease in a New Era of Therapies
title_sort	women and diabetes: preventing heart disease in a new era of therapies
publisher	Radcliffe Medical Media
publishDate	2021
url	https://doaj.org/article/ec4ff1ff8efb43c3b5eb45f3380f1784
work_keys_str_mv	AT giuseppegalati womenanddiabetespreventingheartdiseaseinaneweraoftherapies AT pierresabouret womenanddiabetespreventingheartdiseaseinaneweraoftherapies AT olgagermanova womenanddiabetespreventingheartdiseaseinaneweraoftherapies AT deepaklbhatt womenanddiabetespreventingheartdiseaseinaneweraoftherapies
_version_	1718372708377427968

Women and Diabetes: Preventing Heart Disease in a New Era of Therapies

Ejemplares similares